These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 15507085)
1. Switching from donepezil or rivastigmine to galantamine in clinical practice. Edwards K; Therriault O'connor J; Gorman C J Am Geriatr Soc; 2004 Nov; 52(11):1965. PubMed ID: 15507085 [No Abstract] [Full Text] [Related]
2. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease. Loveman E; Green C; Kirby J; Takeda A; Picot J; Payne E; Clegg A Health Technol Assess; 2006 Jan; 10(1):iii-iv, ix-xi, 1-160. PubMed ID: 16409879 [TBL] [Abstract][Full Text] [Related]
3. Predictors of adherence among Alzheimer's disease patients receiving oral therapy. Borah B; Sacco P; Zarotsky V Curr Med Res Opin; 2010 Aug; 26(8):1957-65. PubMed ID: 20569067 [TBL] [Abstract][Full Text] [Related]
4. Anticholinesterase duration in the Australian veteran population. Gadzhanova S; Roughead L; Mackson J Aust N Z J Psychiatry; 2010 May; 44(5):469-74. PubMed ID: 20397790 [TBL] [Abstract][Full Text] [Related]
5. Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer's disease: systematic review of the 'real-world' evidence. Lockhart IA; Mitchell SA; Kelly S Dement Geriatr Cogn Disord; 2009; 28(5):389-403. PubMed ID: 19893314 [TBL] [Abstract][Full Text] [Related]
6. Cholinesterase inhibitors in the treatment of dementia. Ellis JM J Am Osteopath Assoc; 2005 Mar; 105(3):145-58. PubMed ID: 15863734 [TBL] [Abstract][Full Text] [Related]
7. [Use of acetylcholinesterase inhibitors and memantine in Alzheimer-type dementia]. Portela Romero M; Pombo Romero J; Bugarín González R; Tasende Souto M; Represa Veiga S Rev Esp Salud Publica; 2005; 79(6):665-72. PubMed ID: 16457058 [TBL] [Abstract][Full Text] [Related]
9. Safety and tolerability of rivastigmine transdermal patch compared with rivastigmine capsules in patients switched from donepezil: data from three clinical trials. Sadowsky CH; Farlow MR; Meng X; Olin JT Int J Clin Pract; 2010 Jan; 64(2):188-93. PubMed ID: 20089009 [TBL] [Abstract][Full Text] [Related]
11. Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis. Dybicz SB; Keohane DJ; Erwin WG; McRae T; Shah SN Am J Geriatr Pharmacother; 2006 Jun; 4(2):154-60. PubMed ID: 16860262 [TBL] [Abstract][Full Text] [Related]
14. No donepezil discontinuation effect in patients with Alzheimer's disease who were switched to rivastigmine after failing to benefit from donepezil treatment. Auriacombe S; Pere JJ; Curr Med Res Opin; 2003; 19(8):715-7. PubMed ID: 14687442 [No Abstract] [Full Text] [Related]
15. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease. Bullock R; Bergman H; Touchon J; Gambina G; He Y; Nagel J; Lane R Curr Med Res Opin; 2006 Mar; 22(3):483-94. PubMed ID: 16574032 [TBL] [Abstract][Full Text] [Related]
16. An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting. Aguglia E; Onor ML; Saina M; Maso E Curr Med Res Opin; 2004 Nov; 20(11):1747-52. PubMed ID: 15537474 [TBL] [Abstract][Full Text] [Related]
17. Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease. Ritchie CW; Ames D; Clayton T; Lai R Am J Geriatr Psychiatry; 2004; 12(4):358-69. PubMed ID: 15249273 [TBL] [Abstract][Full Text] [Related]
19. Drug therapy of dementia in elderly patients. A review. Olsen CE; Poulsen HD; Lublin HK Nord J Psychiatry; 2005; 59(2):71-7. PubMed ID: 16195103 [TBL] [Abstract][Full Text] [Related]
20. Comparative analysis of mortality in patients with Alzheimer's disease treated with donepezil or galantamine. López-Pousa S; Olmo JG; Franch JV; Estrada AT; Cors OS; Nierga IP; Gelada-Batlle E Age Ageing; 2006 Jul; 35(4):365-71. PubMed ID: 16788079 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]